AcquisitionOther
GSK plc acquired RAPT Therapeutics
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
GSK plc -> RAPT Therapeutics · $58.00 per share
To acquire ozureprubart, a potentially best-in-class anti-IgE antibody for prophylactic protection against food allergens.
Open source record (SEC) ↗